Menu Search
Equities

Clearpoint Neuro Inc

CLPT:NAQ

Clearpoint Neuro Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)11.65
  • Today's Change-1.77 / -13.19%
  • Shares traded701.86k
  • 1 Year change+98.13%
  • Beta1.0786
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Clearpoint Neuro Inc had net income fall 34.40% from a loss of 16.44m to a larger loss of 22.09m despite a 16.56% increase in revenues from 20.55m to 23.96m. An increase in the selling, general and administrative costs as a percentage of sales from 92.30% to 101.65% was a component in the falling net income despite rising revenues.
Gross margin59.85%
Net profit margin-64.06%
Operating margin-66.17%
Return on assets-35.89%
Return on equity-60.40%
Return on investment-46.51%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Clearpoint Neuro Inc fell by 4.48m. However, Cash Flow from Investing totalled 8.95m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 13.72m for operations while cash generated from financing totalled 296.00k.
Cash flow per share-0.672
Price/Cash flow per share--
Book value per share1.16
Tangible book value per share1.14
More ▼

Balance sheet in USDView more

Clearpoint Neuro Inc appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio2.79
Quick ratio2.31
Total debt/total equity0.3106
Total debt/total capital0.237
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.